TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 274 participants.
Also called NCT07821008
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 274 participants
- Registry
-
NCT07821008
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07821008. Randomized; double masking; primary purpose treatment. Start 2026-11-24 (anticipated); primary completion 2029-12-14 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
- Acronym
- TALISCHER-SAH
- Condition
- Subarachnoid Hemorrhage, Aneurysmal
- Condition
- Brain Ischemia
- Condition
- Endovascular Procedure
- Intervention (Drug)
- Experimental group: ticagrelor
- Intervention (Drug)
- Control group: placebo
- Lead sponsor
- University Hospital, Toulouse
Record details
- Record id
cardio:ct-nct07821008- Content hash
08dbb10f111c2c8374da497d89c841483c32d0c7dbc9f82f33ed6ba18008e3da